ArticleNature and science of sleep2025
Serum Metabolomic Signatures of Dyslipidemia in Narcolepsy Type 1: A Multi-Center Cross-Sectional Study.
Article in Nature and science of sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study Objectives: We aimed to explore the candidate metabolic pathways involved in narcolepsy type 1 (NT1)-related dyslipidemia. Methods: Forty-four patients with NT1, and 44 controls were included in this multicenter metabolomics study. All participants included underwent an overnight polysomnography and multiple sleep latency test. Fasting blood samples were collected to assess lipid levels, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG). Serum metabolomics was used to explore characteristic metabolites in the discovery and validation sets. Results: Patients with NT1 had higher values for TC (5.13 ± 0.14 vs 4.63 ± 0.14 mmol/L, Conclusion: Increased serum glutamate level is associated with decreased level of HDL-C in patients with NT1. Arginine metabolism dysfunction may contribute to dyslipidemia in NT1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.